if we hit $5 you'll be able to fly business class on Delta or Virgin, but I hear you on the smaller airport preference.
BF, you obviously didn't follow the SP and vol movement in June prior to the partial lift on the MC's MF 1ST NDA. Same start as yesterday. We had a 50% SP increase within 3 days. This time it could be much more.
``8.Other papers on Imetelstat expected at ASH``
this should read.... AML & MLS data yet to be presented by Tefferi outside of ASH.
we hit 3.4mil shares with a 10 cent pop, SP dropped back down this afternoon on lower vol. and an ugly market. All points to a positive change in sentiment on GERN.
we all witnessed the FDA halt decision leak 3 days bfr Scarlet got the official news from the FDA, hedgefunds covered their short positions and both vol. & SP increased. So don't go pointing fingers at what's acceptable or not. Leaks happen, that's why you need depends.
what a whole 7 cents worth?
Today GERN's SP broke out for the first time above the descending trend line from January almost 6 wks bfr the FDA hold was made public. A strong indicator of a reversal it appears.
Shorts will attempt to keep the SP from getting away on them but with any +ve catalyst GERN will reset a new trajectory.
all this talk of increased vol. and penetration E2 is getting me all excited. Hope we see a big rise in SP soon.
The news on June 13th was preceded by an increase in vol from a similar 1.2 mil share vol. to 2.4mil shares, 7 the next and then the pop. Yesterday we saw 2.4 million.
and you wonder why airlines don't make any money? Did you at least get the complimentary bag of off colored chips?
"does not mean that the company now can/will proceed to the phase 2 study ....Scarlett said they wouldn't in the last shareholder conference" That is unless the FDA releases the hold in light of current trial data submissions for MF 1ST and GERN's public intent not to pursue the lucrative ET indications, currently a protected market by FDA approval panel lobbyists.
was no coincidence. The markets opened and the hedges shorted. This in light of two major war fronts erupting simultaneously. My guess is that it will pop later this week when investors get spooked out of their equities and hedgies have picked up more shares to sell them.
Numonafide, will be evaluated for the treatment of patients with Acute Myeloid Leukemia (AML).
Imetelstat already has shown remissions in MF 1ST IND NCT 017319 studies with intention to study MF/ AML & MDA
Congrats on John's continued remission. Glad to hear from you as always Irish. Concerned over Jakafi snipers taking shots especially on this board; keep wearing that BP Imet flack jacket. As you say the new IWG established end points in Phase II and Phase II trials is a game changer for MF II/III studies going forward. IMET; a first in class MF remission drug
In time GERN will be going after a much wider range of AML's or ANLL's . KITE's c-19 is in phase 1 as is GERN's but neither space has approved first in class drugs yet. I'm not an oncologist but as a beaver I would think these drugs have totally different mechanisms at work on totally different forms of cancer. Combinations of these and other oncology drugs could produce much wider potential applications for treatment. Look at Jakafi many indications as a comfort breakfast cereal topping.
Imetelstat promising first in class efficacy results in MAYO's MF-1 studies is likely to work in other myeloproliferative disorders (MDS, PV, AML) as well as MF
With further AML or MDS data Tefferi has yet to present SP could easily catch up to KITE's SP in short order.
positive results from an ongoing phase I-IIa study on KTE-C19 in patients suffering from aggressive non-Hodgkin's lymphoma(NHL) in the Aug 25, 2014 issue of the American Society of Clinical Oncology's Journal of Clinical Oncology. In the phase I-II study, KTE-C19 achieved 92% overall objective response rate.
out of 13 patients with advanced B-cell malignancies (including 7 patients with chemotherapy-refractory diffuse large B cell lymphoma (:DLBCL)), 8 achieved complete remission, while 4 achieved partial remission. Additionally, 4 of the 7 chemotherapy-refractory DLBCL patients
achieved complete remission, while 2 showed partial remission. Among these 4 patients, 3 are showing ongoing complete responses with durations ranging from 9 to 22 months.
Imetelstat sounds similarly as effective in treating MF (bone marrow fibrosis)
non-Hodgkin's lymphoma (NHL) originates in the lymph nodes, bone marrow fibrosis (MF) cancer originates in bone marrow. Two different blood cancers requiring two different treatments. Mind you I'd prefer their SP over GERN's right now.